Psychiatric effects and side effects of the alpha-2-antagonist yohimbine: Areview of literature and case report;Yohimbin, ein alpha-2-antagonist: Literaturübersicht zu psychiatrisch relevanten Wirkungen und nebenwirkungen mit aktuellem fallbericht

Fortschritte der Neurologie Psychiatrie

Volumn 77, Issue 10, 2009, Pages 585-590

  Scherr, M ^a   Schwerthoeffer, D ^a   Froboese, T ^a   Castrop, F ^a   Bauml J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alcohol; Behaviorial alterations; Cocaine; Suicidality; Yohimbine

Indexed keywords

ALCOHOL; COCAINE; ESCITALOPRAM; MIRTAZAPINE; YOHIMBINE;

ADULT; ANAMNESIS; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CLINICAL STUDY; COCAINE DEPENDENCE; DEFENSIVE BEHAVIOR; DETERIORATION; DRUG EFFECT; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEAR; FEMALE; HUMAN; HYPOTHESIS; INTOXICATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PANIC; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGIC ASSESSMENT; STRESS; SUICIDAL IDEATION; WEIGHT GAIN; WEIGHT REDUCTION;

ADRENERGIC ALPHA-ANTAGONISTS; ALCOHOLISM; ANXIETY; COCAINE-RELATED DISORDERS; FEMALE; HUMANS; MENTAL DISORDERS; SUICIDE; YOHIMBINE; YOUNG ADULT;

EID: 70449440411     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0028-1109758     Document Type: Article

References (44)

1. Vogt H J., Brandl P, Kockott G, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 1997 9 (3) 155-161
2. Becker A J., Mayer M, Stief C G. Therapy for organic erectile Dysfunction. Urologe A 2005 44 (10) 1160-1166
3. Derouet H, Osterhage J, Sittinger H. Erectile function disorders. Epidemiology, physiology, etiology, diagnosis and therapy. Nervenarzt 2004 75 (6) 595-605, quiz 606 607
4. Giampreti A, Lonati D, Locatelli C, et al. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol 2009 Epub ahead of print 30.7.2009
5. Crespi F. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety. JNeurosci Methods 2009 180 (1) 97-105
6. Vasa R A., Pine D S., Masten C L., et al. Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology 2009 204 (3) 445-455
7. Buffalari D M., Grace A A. Anxiogenic Modulation of Spontaneous and Evoked Neuronal Activity in the Basolateral Amygdala. Neuroscience 2009 Epub ahead of print 7.7.2009
8. Bremner J D., Innis R B., Ng C K., et al. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Arch Gen Psychiatry 1997 54 246-254
9. Southwick S M., Morgan III C A., Charney D S., et al. Yohimbine use in a natural setting: effects on posttraumatic stress disorder. Biol Psychiatry 1999 46 442-444
10. Morgan 3 rd C A., Grillon C, Southwick S M., et al. Yohimbine facilitated acoustic startle reflex in combat veterans with post-traumatic stress disorder. Psychopharmacology 1995 117 466-471
11. Charney D S., Heninger G R., Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1984 41 751-763
12. Gurguis G N., Vitton B J., Uhde T W. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 1997 71 (1) 27-39
13. Myers E A., Banihashemi L, Rinaman L. The anxiogenic drug yohimbine activates central viscerosensory circuits in rats. JComp Neurol 2005 492 (4) 426-441
14. Blanchard R J., Taukulis H K., Rodgers R J., et al. Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. Pharmacol Biochem Behav 1993 44 (3) 673-681
15. Haller J, Kiem D T., Makara G B. Do alpha-2 adrenoceptors modify coping strategies in rats? Psychopharmacology 1995 122 (4) 379-385
16. Mann J J. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003 4 (10) 819-828
17. Huang Y Y., Cate S P., Battistuzzi C, et al. An association between a functional polymorphism in the monoamine oxidase a gene promoter, impulsive traits and early abuse experiences. Neuropsychopharmacology 2004 29 (8) 1498-1505
18. Carballo J J., Akamnonu C P., Oquendo M A. Neurobiology of suicidal behavior. An integration of biological and clinical findings. Arch Suicide Res 2008 12 (2) 93-110
19. Gos T, Krell D, Bielau H, et al. Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. Eur Arch Psychiatry Clin Neurosci 2008 258 (8) 513-520
20. Meana J J., Barturen F, García-Sevilla J A. Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 1992 31 (5) 471-490
21. González-Maeso J, Rodríguez-Puertas R, Meana J J., et al. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)- adrenoceptors. Mol Psychiatry 2002 7 (7) 755-767
22. Arango V, Underwood M D., Pauler D K., et al. Differential age-related loss of pigmented locus coeruleus neurons in suicides, alcoholics, and alcoholic suicides. Alcohol Clin Exp Res 1996 20 (7) 1141-1147
23. Ordway G A., Widdowson P S., Smith K S., et al. Agonist binding to alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. JNeurochem 1994 63 (2) 617-624
24. Escribá P V., Ozaita A, García-Sevilla J A. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 2004 29 (8) 1512-1521
25. Arango V, Ernsberger P, Sved A F., et al. Quantitative autoradiography of alpha 1- and alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 1993 630 (1 2) 271-282
26. Emanuele E, Minoretti P, Arra M. Yohimbine may have a therapeutic role in prevention of suicide by regulation of glial fibrillary acidic protein expression. Med Hypotheses 2006 67 (6) 1472
27. Feltenstein M W., See R E. Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine. Behav Brain Res 2006 174 (1) 1-8
28. Kupferschmidt D A., Tribe E, Erb S. Effects of repeated yohimbine and extinction and reinstatement of cocaine seeking. Pharmacol Biochem Behav 2009 91 473-480
29. Wee S, Mandyam C D., Lekic D M., et al. Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 2008 18 303-311
30. Jiménez-Rivera C A., Feliu-Mojer M, Vázquez-Torres R. Alpha-noradrenergic receptors modulate the development and expression of cocaine sensitization. Ann N Y Acad Sci 2006 1074 390-402
31. Davis A R., Shields A D., Brigman J L., et al. Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process. Learn Mem 2008 15 667-776
32. Richards J K., Simms J A., Bartlett S E. Conditioned cues and yohimbine induce reinstatement of beer and near-beer seeking in Long-Evans rats. Addict Biol 2009 14 144-151
33. Richards J K., Simms J A., Steensland P, et al. Inhibition of orexin-1 /hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology 2008 199 109-117
34. Marinelli P W., Funk D, Juzytsch W, et al. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology 2007 195 345-355
35. Dzung L e A, Funk D, Harding S, et al. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. Psychopharmacology 2009 204 477-488
36. McDougle C J., Krystal J H., Price L H., et al. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine. Psychopharmacology 1995 118 127-135
37. Stine S M., Southwick S M., Petrakis I L., et al. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 2002 51 642-651
38. Milne B, Sutak M, Cahill C M., et al. Low doses of alpha 2-adrenoreceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol 2008 155 1264-1278
39. Powers M B., Smits J A., Otto M W., et al. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. JAnxiety Disord 2009 23 350-356
40. Mueller D, Olivera-Figueroa L A., Pine D S., et al. The effects of yohimbine and amphetamine on fear expression and extinction in rats. Psychopharmacology 2009 204 599-606
41. Imaki J, Mae Y, Shimizu S, et al. Therapeutic potential of alpha2 adrenoreceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett 2009 454 143-147
42. Sanacora G, Berman R M., Cappiello A, et al. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology 2004 29 1166-1171
43. Mavanji V, Datta S. Sleep-wake effects of yohimbine and atropine in rats with a clomipramine-based model of depression. Neuroreport 2002 13 1603-1606
44. Schank J R., Liles L C., Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry 2008 63 1007-10 012